Weave

About

Weave Bio is an AI-native life sciences platform based in New Haven, Connecticut, specializing in regulatory automation for drug development. The company focuses on streamlining regulatory submissions, particularly Investigational New Drug (IND) applications, using its AI-powered platform. Weave Bio aims to enhance the efficiency of regulatory workflows for pharmaceutical companies, biotechs, and contract research organizations (CROs). The flagship product, AutoIND, automates the preparation, drafting, and review of IND applications, significantly reducing the time required for FDA submission. The Regulatory Automation and Lifecycle Management (ReALM) platform supports comprehensive regulatory processes, offering features like AI-augmented drafting, data organization, and collaborative review tools. Weave Bio has received recognition for its innovative approach, including a $10 million seed funding round and the 2024 BioTech AI Innovation of the Year Award. The company is dedicated to empowering regulatory teams to focus on strategic decision-making by integrating AI into their workflows.